Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. — المؤلف: Criss, Steven D — JAMA oncology 20191219
- المؤلف
- Criss, Steven D
- النشر
- JAMA oncology 20191219
- الوصف
- 358-365 p.
- الموضوعات
- Antibodies, Monoclonal؛ Antineoplastic Agents, Immunological؛ Budgets؛ Carcinoma, Non-Small-Cell Lung؛ Chemoradiotherapy؛ Consolidation Chemotherapy؛ Cost-Benefit Analysis؛ Decision Support Techniques